Clinical Trials
11 trialsNCT03213704 2026-06-02
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03367741 2026-06-02
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03660826 2026-06-02
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04458922 2026-06-02
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03155620 2026-06-01
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02408861 2026-01-21
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04751383 2026-01-21
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT02595866 2024-08-09
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00686842 2018-06-06
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
AIDS Malignancy Consortium
Phase 1/2 Terminated
NCT02150213 2016-12-05
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Novartis
Phase 2 Completed
NCT00233948 2015-04-01
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
City of Hope Medical Center
Phase 1/2 Terminated